ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $192.80.

ICUI has been the subject of several recent analyst reports. Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Piper Sandler increased their target price on shares of ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Needham & Company LLC boosted their price target on shares of ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th.

Insider Transactions at ICU Medical

In other news, COO Christian B. Voigtlander sold 8,929 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the sale, the chief operating officer directly owned 37,377 shares of the company’s stock, valued at approximately $6,837,374.61. The trade was a 19.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elisha W. Finney sold 378 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the completion of the sale, the director directly owned 4,871 shares of the company’s stock, valued at $888,860.08. The trade was a 7.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 16,974 shares of company stock worth $3,085,844 over the last three months. 2.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICUI. BlackRock Inc. acquired a new stake in shares of ICU Medical in the second quarter valued at approximately $550,250,000. Jupiter Topco LLC purchased a new position in shares of ICU Medical during the second quarter worth approximately $407,786,000. Millennium Management LLC grew its position in shares of ICU Medical by 173.4% during the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after acquiring an additional 690,694 shares during the last quarter. Norges Bank acquired a new position in shares of ICU Medical in the 4th quarter valued at $58,083,000. Finally, Reinhart Partners LLC. acquired a new position in shares of ICU Medical in the 2nd quarter valued at $46,148,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

ICUI stock opened at $182.98 on Friday. The business has a 50 day moving average price of $156.56 and a 200 day moving average price of $141.96. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.57 billion, a price-to-earnings ratio of 155.07, a PEG ratio of 2.56 and a beta of 0.74. ICU Medical has a fifty-two week low of $112.50 and a fifty-two week high of $192.85.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same period in the prior year, the firm posted $2.10 earnings per share. The firm’s revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts anticipate that ICU Medical will post 6.51 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.